At Ochsner Cancer Center of Acadiana, people diagnosed with blood cancers find more than the latest treatments — they also ...
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint ...
Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...
FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data ...
Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, ...
A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the ...
Zacks Investment Research on MSN
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash. The acquisition will add OTX-201, an investigational ...
The FDA has approved the combination of lurbinectedin (Zepzelca) and the immunotherapy atezolizumab (Tecentriq) for first-line maintenance treatment in patients with extensive-stage small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback